Instem investor presentation
NettetNumber of securities in issue. The Company’s issued share capital consists of ordinary shares with a nominal value of 10p pence each (“Ordinary Shares”), each share having … Nettet27. okt. 2024 · Instem plc. ('Instem', the 'Company' or the 'Group') Investor Presentation. Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences …
Instem investor presentation
Did you know?
Nettet13. sep. 2024 · Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management … NettetInstem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that, on 20 March 2024, it exchanged contracts to acquire US-based clinical trial technology & consulting leader d-Wise Technologies, Inc ("d-wise") for a total consideration of up to $31m, net of any cash acquired and adjusted for a normalised …
Nettet22. mar. 2024 · Instem plc 22 March 2024 Instem plc ("Instem" or "the Company" or "the Group") Earnings Enhancing ... Instem plc Acquisition of d-wise and Investor Presentation. 22/03/2024 7:00am UK Regulatory (RNS & others) Instem (LSE:INS) Historical Stock Chart. From Feb 2024 to Mar 2024. TIDMINS . RNS Number : 9423S . ... NettetAbout Us. Instem is a leading provider of IT solutions to the global life sciences market which help clients collect, analyze, report and submit data to regulatory agencies with …
Nettet22. mar. 2024 · Acquisition of clinical trial technology & consulting leader and Issue of Equity. Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that, on 20 March 2024, it exchanged contracts to acquire US-based clinical trial technology & consulting leader d-Wise Technologies, Inc ('d-wise') for a … NettetEQUASENS Coté sur Euronext Paris™ – Compartiment AIndices : MSCI GLOBAL SMALL CAP – GAÏA Index 2024 – CAC® SMALL et CAC® All-Tradable par inclusionIntégré au label European Rising TechEligible au Service de Règlement Différé (SRD) et au dispositif PEA-PMEISIN : FR 0012882389 – Code Mnémonique : EQS EQUASENS intègre le …
NettetInstem provides advanced and best-in-class IT solutions to the global health and life sciences community which improves the productivity of their processes in the discovery …
NettetPresentation 1MB Transcript 215KB Video event page. Nov 29, 2024. Q&A Nestlé Health Science - Investor Seminar 2024. Transcript 190KB Video event page. Nov 29, 2024. Medical Nutrition: Solutions to address specific medical needs, Anna Mohl - Investor Seminar 2024. Presentation 2MB Transcript 200KB Video event page. Nov 29, 2024. dr ahmed goolam reviewsNettet27. okt. 2024 · Media/Events dr ahmed gastroenterologist anderson indianaNettet30. jun. 2024 · Analysts wishing to join should register their interest by emailing [email protected] or by telephoning 020 7933 8780. Investor Presentation: … emma wismerNettet27. okt. 2024 · Instem plc ("Instem" or "the Company") Investor Presentation Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, will be hosting a presentation through the digital platform, Investor Meet Company, at 16.30 on the afternoon of 04 November 2024. The Company will discuss recent results, where it … dr. ahmed gi wesley chapelNettetInstem plc ("Instem" or "the Company") Investor Presentation Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, will be hosting a … dr ahmed greencastleNettet14. sep. 2024 · Investor Presentation: 4.00pm, Monday 27 September Management will be providing a presentation and hosting an Investor Q&A session on the results and future prospects, as well as the recent acquisition of PDS Pathology Data Systems Ltd on the day of results, at 4.00pm. Investors can sign up for free and add to attend the … dr ahmed group healthNettet31. des. 2024 · Unaudited Results for the Year Ended 31 December 2024 & Investor Presentation. Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces its unaudited results for the year ended 31 December 2024 (the "Period"). Recurring revenue (annual support and SaaS) increased 43% to £24.1m … dr ahmed hassan gastroenterologist